Aptinyx (NASDAQ:APTX) Shares Up 6.8%
Aptinyx Inc (NASDAQ:APTX)’s stock price shot up 6.8% on Thursday . The stock traded as high as $3.97 and last traded at $3.94, 297,342 shares changed hands during trading. A decline of 14% from the average session volume of 347,107 shares. The stock had previously closed at $3.69.
A number of equities research analysts have recently commented on APTX shares. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Aptinyx in a research note on Thursday, June 18th. SunTrust Banks started coverage on Aptinyx in a research note on Wednesday, July 1st. They set a “buy” rating and a $15.00 target price on the stock. William Blair started coverage on Aptinyx in a research note on Thursday, May 7th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded Aptinyx from a “sell” rating to a “hold” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Aptinyx presently has an average rating of “Buy” and an average price target of $7.81.
The firm has a market cap of $172.14 million, a PE ratio of -2.43 and a beta of 1.48. The stock has a fifty day simple moving average of $4.32 and a two-hundred day simple moving average of $3.50.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UBS Group AG grew its stake in shares of Aptinyx by 2,549.0% in the second quarter. UBS Group AG now owns 7,947 shares of the company’s stock worth $33,000 after acquiring an additional 7,647 shares during the last quarter. Spark Investment Management LLC grew its stake in shares of Aptinyx by 53.5% in the first quarter. Spark Investment Management LLC now owns 33,316 shares of the company’s stock worth $71,000 after acquiring an additional 11,616 shares during the last quarter. DCF Advisers LLC grew its stake in shares of Aptinyx by 15.9% in the first quarter. DCF Advisers LLC now owns 105,800 shares of the company’s stock worth $229,000 after acquiring an additional 14,500 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Aptinyx in the first quarter worth $32,000. Finally, Morgan Stanley grew its stake in shares of Aptinyx by 22.0% in the first quarter. Morgan Stanley now owns 89,189 shares of the company’s stock worth $193,000 after acquiring an additional 16,092 shares during the last quarter. 56.64% of the stock is currently owned by hedge funds and other institutional investors.
About Aptinyx (NASDAQ:APTX)
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Featured Article: How to Invest in an Index Fund
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.